Anti-Depressant Therapy Brightens the Outlook for Prostate Cancer Bone Metastases

Publication date: 13 March 2017
Source:Cancer Cell, Volume 31, Issue 3
Author(s): Michael D. Nyquist, Peter S. Nelson
In this issue of Cancer Cell, Wu et al. identify MAOA as a key mediator of osteolytic bone responses that involve complex paracrine interactions between tumor cells, osteoblasts, and osteoclasts. Pharmacological inhibition of MAOA enzymatic activity effectively interrupted osteolysis and metastatic progression in preclinical models, suggesting a new treatment opportunity.

Teaser

In this issue of Cancer Cell, Wu et al. identify MAOA as a key mediator of osteolytic bone responses that involve complex paracrine interactions between tumor cells, osteoblasts, and osteoclasts. Pharmacological inhibition of MAOA enzymatic activity effectively interrupted osteolysis and metastatic progression in preclinical models, suggesting a new treatment opportunity.


http://ift.tt/2mn6EAh